Edgewise Therapeutics (EWTX) Non-Current Assets (2020 - 2026)

Edgewise Therapeutics has reported Non-Current Assets for 7 years, with the latest figure at $8.7 million in Q1 2026.

• Quarterly Non-Current Assets fell 22.14% year-over-year to $8.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.6 million (down 19.33% YoY) and the FY2025 annual result came in at $9.2 million, down 18.67% from the prior year.
• Non-Current Assets declined to $8.7 million in Q1 2026 per EWTX's latest filing, from $9.2 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $13.6 million in Q2 2023 and troughed at $4.1 million in Q2 2022.
• A 5-year average of $10.3 million and a median of $11.2 million in 2025 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2026: Non-Current Assets jumped 674.05% in 2022, then declined 22.14% in 2026.
• Over 5 years, Non-Current Assets stood at $10.1 million in 2022, then climbed by 29.06% to $13.0 million in 2023, then retreated by 13.07% to $11.3 million in 2024, then fell by 18.67% to $9.2 million in 2025, then declined by 5.29% to $8.7 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $8.7 million, $9.2 million, and $9.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.